Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-07-01 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
公司章程（2021年7月）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Shenzhen Salubris Pharmaceuticals Co., Ltd., dated July 2021. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. There is no indication that this is an annual report, financial statement, or any other type of financial or regulatory filing. Instead, it is a governance document that sets out the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains the full text of the company's articles, not just an announcement or summary, so it is not an RPA or RNS.
2021-07-01 Chinese
《公司章程》修正案
Governance Information Classification · 95% confidence The document is a detailed amendment to the company's Articles of Association (公司章程) reflecting changes in registered capital and share structure following a non-public stock issuance. It includes specific revisions to the company's charter clauses, share capital figures, and shareholder information. The document is not a full annual or interim financial report, nor is it an announcement of voting results or a proxy statement. It is a governance-related document detailing internal company rules and capital structure changes. The document length is 2425 characters, which is relatively short but contains substantive content about the company's governance and capital structure amendments. Therefore, the most appropriate classification is Governance Information (CGR).
2021-07-01 Chinese
关于使用募集资金向成都子公司增资并实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. to increase capital in its wholly-owned subsidiary and implement investment projects. It details the approval by the board, the amount of funds raised through a non-public stock issuance, the investment projects, and the financial status of the subsidiary. The document includes opinions from independent directors, the supervisory board, and the sponsoring institution, and it is structured as a formal announcement to shareholders and the public. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or other report types. The document is a formal disclosure about capital use and investment, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it contains substantive information about the capital increase and fund usage. Therefore, the best classification is CAP with high confidence.
2021-07-01 Chinese
第五届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes decisions on the use of raised funds, amendments to the articles of association, capital increase, and plans to convene a shareholders' meeting. The document is titled as a "Board of Directors Meeting Resolution Announcement" and contains no financial statements or detailed financial data. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results announcement. The content fits the category of Board/Management Information (MANG), as it reports on board meeting decisions and management resolutions.
2021-07-01 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司使用募集资金向全资子公司增资并实施募投项目的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a securities company regarding the use of raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. to increase capital in its wholly-owned subsidiary and implement investment projects. It includes specifics about the fundraising, investment projects, capital increase plan, company details, financial data, and opinions from the board, supervisory committee, independent directors, and the sponsor institution. The document references regulatory approvals and compliance with stock exchange rules. It is not a full annual or interim financial report, nor is it a brief announcement or certification. It is a specialized audit or verification report related to the use of raised funds and compliance with regulatory requirements. Therefore, it fits best under Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content and detailed verification opinions, not just an announcement of a report publication, so it is not RPA or RNS. Q1 2021
2021-07-01 Chinese
独立董事关于公司有关事项所发表的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion statement from independent directors regarding the company's use of raised funds, compliance with regulations, and approval of related financial decisions. It references regulatory guidelines and confirms the legality and appropriateness of the company's actions concerning fundraising and fund usage. The document is relatively short (1523 characters) and does not contain detailed financial statements or comprehensive financial performance data. It is not an annual report, audit report, or interim report. Instead, it is a formal opinion related to governance and compliance matters concerning capital use. This type of document aligns best with Regulatory Filings (RNS), as it is a compliance-related statement without substantive financial data or report content.
2021-07-01 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.